Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1543-1549

  Cai, Mu Yan ^a,b   Zhang, Bin ^a   He, Wei Peng ^c   Yang, Guo Fen ^c   Rao, Hui Lan ^a,b   Rao, Zhi Yue ^a   Wu, Qiu Liang ^b   Guan, Xin Yuan ^a   Kung, Hsiang Fu ^a   Zeng, Yi Xin ^a   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Cancer Center   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CYSTADENOMA; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY; OVARY CARCINOMA; PINX1 TUMOR SUPPRESSOR GENE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TELOMERASE; TUMOR SUPPRESSOR PROTEINS;

EID: 77954153940     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01560.x     Document Type: Article

References (29)

1. Lynch HT, Casey MJ, Lynch J, White TE, Godwin AK. Genetics and ovarian carcinoma. Semin Oncol 1998, 25:265-80.
2. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994, 10:31-46.
3. Engel J, Eckel R, Schubert-Fritschle G. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002, 38:2435-45.
4. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000, 82:1535-8.
5. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res 2000, 6:1372-7.
6. Bova GS, Carter BS, Bussemakers MJ. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993, 53:3869-73.
7. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 1996, 35:46-54.
8. Kishimoto Y, Shiota G, Wada K. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1996, 122:585-9.
9. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996, 35:55-65.
10. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001, 107:347-59.
11. Zhang B, Bai YX, Ma HH. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res 2009, 69:75-83.
12. Xie D, Sham JS, Zeng WF. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003, 107:896-902.
13. Xie D, Zeng YX, Wang HJ. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006, 94:108-14.
14. Ma Y, Wu L, Liu C, Xu L, Li D, Li JC. The correlation of genetic instability of PINX1 gene to clinico-pathological features of gastric cancer in the Chinese population. J Cancer Res Clin Oncol 2009, 135:431-7.
15. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007, 60:1112-6.
16. Zlobec I, Minoo P, Baker K. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer 2007, 43:1101-7.
17. Zlobec I, Vuong T, Hayashi S. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007, 96:793-800.
18. Zlobec I, Steele R, Michel RP, Compton CC, Lugli A, Jass JR. Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol 2006, 19:1236-42.
19. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 2005, 98:396-402.
20. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989, 29:307-35.
21. Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK. Molecular analysis of PinX1 in medulloblastomas. Int J Cancer 2004, 109:309-14.
22. Liao C, Zhao MJ, Zhao J. Mutation analysis of novel human liver-related putative tumor suppressor gene in hepatocellular carcinoma. World J Gastroenterol 2003, 9:89-93.
23. Park WS, Lee JH, Park JY. Genetic analysis of the liver putative tumor suppressor (LPTS) gene in hepatocellular carcinomas. Cancer Lett 2002, 178:199-207.
24. Hawkins GA, Chang BL, Zheng SL. Mutational analysis of PINX1 in hereditary prostate cancer. Prostate 2004, 60:298-302.
25. Lugli A, Zlobec I, Gunthert U. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol 2006, 19:1302-9.
26. Kondo T, Oue N, Mitani Y. Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene 2005, 24:157-64.
27. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006, 96:73-81.
28. Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005, 7:1-2.
29. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett 2003, 194:209-19.